Pre-Made Eflepedocokin Alfa Biosimilar, Fusion Protein targeting IL10RB fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CDW210B/CRF2-4/CRFB4/D21S58/D21S66/IL-10R2 for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-819

Pre-Made Eflepedocokin Alfa Biosimilar, Fusion Protein targeting IL10RB fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CDW210B/CRF2-4/CRFB4/D21S58/D21S66/IL-10R2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

In general, IL-22 protects against epithelial cell injury and reduces bacterial infection, thereby inhibiting inflammation. However, IL-22 has also been implicated in promoting inflammation under certain conditions, which raises some concerns about IL-22 therapy. Eflepedocokin Alfa is a recombinant fusion protein consisting of two human interleukin-22 (IL-22) molecules linked to an immunoglobulin constant region (IGG2-FC).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-819-1mg 1mg 3090
GMP-Bios-INN-819-10mg 10mg Inquiry
GMP-Bios-INN-819-100mg 100mg Inquiry
GMP-Bios-INN-819-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Eflepedocokin Alfa Biosimilar, Fusion Protein targeting IL10RB fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CDW210B/CRF2-4/CRFB4/D21S58/D21S66/IL-10R2
INN Name Eflepedocokin Alfa
TargetIL10RB
FormatFusion Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFusion - IL22 (interleukin 22, IL- 22, ILTIF, IL-TIF) - IGHG2 Fc (Fragment constant)
VD LCFusion - IL22 (interleukin 22, IL- 22, ILTIF, IL-TIF) - IGHG2 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesGeneron Corporation (Shanghai) Ltd. (Shanghai China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0